What is Standard Imaging?
Standard Imaging operates as a pivotal player in the radiation therapy ecosystem, specializing in advanced quality assurance (QA) solutions. The company provides a comprehensive suite of products, including electrometers, phantoms, and sophisticated software platforms tailored for medical physicists and dosimetrists. By automating and refining daily, monthly, and annual QA processes, the firm enables healthcare providers to maintain the highest standards of precision in cancer treatment delivery.
Their market position is defined by a deep integration into the clinical workflow, where their next-generation hardware, such as the MAX Elite Electrometer, serves as a benchmark for reliability. Through a focus on innovation and technical excellence, Standard Imaging has established itself as an indispensable partner for oncology departments globally, ensuring that complex radiation therapy equipment operates within strict safety and efficacy parameters.
How much funding has Standard Imaging raised?
Standard Imaging has raised a total of $2.1M across 2 funding rounds:
Debt
$1M
Debt
$1.1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.1M led by PPP
Key Investors in Standard Imaging
PPP
Public-Private Partnership
What's next for Standard Imaging?
With the recent strategic investment, Standard Imaging is well-positioned to accelerate its research and development initiatives, particularly in the realm of automated QA software and next-generation dosimetry hardware. The company is expected to focus on expanding its footprint in international markets while deepening its technological moat through the integration of advanced data analytics into its existing product ecosystem.
Looking ahead, the firm will likely prioritize the scaling of its service infrastructure to support the growing complexity of modern radiation therapy delivery systems. By maintaining its focus on the intersection of medical physics and software engineering, Standard Imaging is poised to navigate the evolving regulatory landscape and continue its growth as a leader in clinical quality assurance.
